etoposide IV

P2, N=115, Active, not recruiting, St. Jude Children's Research Hospital | Trial primary completion date: Dec 2025 --> Dec 2026

P2, N=18, Recruiting, University of Washington | Not yet recruiting --> Recruiting

P1, N=46, Active, not recruiting, Boehringer Ingelheim | Trial primary completion date: Dec 2025 --> Sep 2026

P2, N=28, Recruiting, Roswell Park Cancer Institute | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jul 2027

P1, N=53, Recruiting, City of Hope Medical Center | Active, not recruiting --> Recruiting | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026

The chalcone 6´-benzyloxy-2´-hydroxy-4-(2-pyridyl)chalcone (BHP) exhibited potency comparable to the antitumor agent etoposide against U-937 cells while showing lower toxicity against human peripheral blood mononuclear cells...In U-937 and HL-60 cells, BHP triggered mitochondrial cytochrome c release, activation of caspases and poly(ADP-ribose) polymerase cleavage and increased annexin-V positive cells. Cell death triggered by BHP was (i) blocked by a pan-caspase inhibitor and by a specific caspase-9 inhibitor, (ii) associated with the phosphorylation of the mitogen-activated protein kinases and (iii) dependent of the generation of reactive oxygen species.

This case highlights the role of genomic profiling test for clinical decision-making as tumor mutational burden predicts the efficacy of immune checkpoint inhibitor therapy in SCCB. This case also underscores the urgent need for novel treatment approaches for SCCB.

In order to improve the efficacy, recent studies have confirmed that the combination of etoposide (CHOPE regimen) on the basis of CHOP regimen can significantly improve the treatment response for newly diagnosed patients aged ≤ 65 years...The patient received four cycles of CHOPE regimen after surgical resection of the primary tumor and underwent PET/CT mid-term evaluation. Through this case, we aim to further explore the pathological diagnosis difficulties of such rare cases and preliminarily evaluate the clinical application value of CHOPE regimen.

In our model, CBD stimulated the cells, as confirmed by modulation of CB2 expression as well as changes in intracellular cAMP. Our results show that CBD in ranges between 5 [Formula: see text] to 50 [Formula: see text] does not significantly increase the amount of DNA double strand breaks in HepG2 cells compared to the control. However, we did observe a significant reduction in cell proliferation and a significant increase in intracellular cAMP levels following CBD treatment.

The patient received the first cycle of the chemotherapy regimen of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide (VAC/IE) and was discharged in a stable condition. This case emphasizes the need to consider EES in the differential diagnosis of nasal masses and highlights the necessity of molecular testing for EWSR1 rearrangements to confirm the diagnosis and guide therapy. Increased awareness and reporting are vital to enhancing diagnosis and management of this rare entity.

P2, N=31, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Dec 2026

P2, N=180, Recruiting, AbbVie | Not yet recruiting --> Recruiting | Phase classification: P2/3 --> P2